Version 1
: Received: 3 April 2019 / Approved: 7 April 2019 / Online: 7 April 2019 (12:35:26 CEST)
How to cite:
Yang, E.; Kang, H.; Rhim, J.; Kang, J.; Lee, K. Early Corticosteroid Therapy for Mycoplasma pneumoniae Pneumonia Irrespective of Used Antibiotics in Children. Preprints2019, 2019040070. https://doi.org/10.20944/preprints201904.0070.v1
Yang, E.; Kang, H.; Rhim, J.; Kang, J.; Lee, K. Early Corticosteroid Therapy for Mycoplasma pneumoniae Pneumonia Irrespective of Used Antibiotics in Children. Preprints 2019, 2019040070. https://doi.org/10.20944/preprints201904.0070.v1
Yang, E.; Kang, H.; Rhim, J.; Kang, J.; Lee, K. Early Corticosteroid Therapy for Mycoplasma pneumoniae Pneumonia Irrespective of Used Antibiotics in Children. Preprints2019, 2019040070. https://doi.org/10.20944/preprints201904.0070.v1
APA Style
Yang, E., Kang, H., Rhim, J., Kang, J., & Lee, K. (2019). Early Corticosteroid Therapy for <em>Mycoplasma pneumoniae</em> Pneumonia Irrespective of Used Antibiotics in Children. Preprints. https://doi.org/10.20944/preprints201904.0070.v1
Chicago/Turabian Style
Yang, E., Jin-Han Kang and Kyung-Yil Lee. 2019 "Early Corticosteroid Therapy for <em>Mycoplasma pneumoniae</em> Pneumonia Irrespective of Used Antibiotics in Children" Preprints. https://doi.org/10.20944/preprints201904.0070.v1
Abstract
Antibiotics’ effect on Mycoplasma pneumoniae (MP) infection still remains controversial. A prospective study of 257 children with MP pneumonia during a recent epidemic (2015-2016) was conducted. All MP pneumonia patients were treated with corticosteroids within 24-36 h after admission. Initially, oral prednisolone (1 mg/kg) or intravenous methylprednisolone (IVMP) (1-2 mg/kg) was administered for mild pneumonia patients, and IVMP (5 -10 mg/kg/day) for severe pneumonia patients. If patients showed persistent fever for 36-48 hours or disease progression, additive IVMP (5 mg/kg or 10 mg/kg) was given. Eighty-five patients received only a broad-spectrum antibiotic without macrolide. The mean age and the male:female ratio were 5.6 ± 3.1 years, respectively. Seventy-four percent of patients (190/257) showed immediate defervescence within 24 h, and 95.7% (246/257) of patients showed defervescence within 72 h with improvements in clinical symptoms. Eight patients who received additive IVMP also showed clinical improvement within 48 h without adverse reactions. There were no clinical or laboratory differences between patients treated with a macrolide (n = 172) and without (n = 85). Early corticosteroid therapy might reduce disease morbidity and prevent disease progression in MP pneumonia patients without side effects, and antibiotics may have limited effects on MP infection.
Medicine and Pharmacology, Pediatrics, Perinatology and Child Health
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
